The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial.

Katarina Mølsæter, Kjetil Roth, Tor Åge Myklebust, Erland Hermansen, Dave Singh, Crawford Currie, Dag Arne Lihaug Hoff

Abstract readRandomized Controlled Trial

In one paragraph

Trial report in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katarina MølsæterDepartment of Health Sciences, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), P.O. Box 1517, 6025 Ålesund, Norway.

Kjetil RothDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), P.O. Box 8905, 7491 Trondheim, Norway.ORCID 0009-0003-8107-5652

Tor Åge MyklebustDepartment for Research and Innovation, Møre og Romsdal Hospital Trust (HMR), P.O. Box 1600, 6026 Ålesund, Norway.

Erland HermansenDepartment of Health Sciences, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), P.O. Box 1517, 6025 Ålesund, Norway.

Dave SinghManchester University NHS Foundation Trust, Wythenshawe, Manchester M23 9L, UK.

Crawford CurrieHofseth Biocare ASA, Keiser Wilhelms g. 24, 6003 Ålesund, Norway.ORCID 0000-0002-4441-5262

Dag Arne Lihaug HoffDepartment of Health Sciences, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), P.O. Box 1517, 6025 Ålesund, Norway.

Funding

The Research Council of Norway 332941

6 · The paper itself

Abstract

Asthma is a heterogeneous chronic respiratory condition with distinct inflammatory phenotypes, including type 2-driven eosinophilic asthma. This randomized, double-blind, placebo-controlled exploratory trial investigated the effects of OmeGO

Indexed as

AsthmaDocosahexaenoic AcidsEicosapentaenoic AcidFish OilsAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeDocosahexaenoic AcidsEicosapentaenoic AcidFish Oilsadultdouble-blindeosinophilic asthmamarine fish oilpro-resolving lipid mediatorsrandomized controlled trialtype 2-inflammation

Identifiers

PMID40863645

DOI10.3390/md23080328

PMCPMC12387695

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.